These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 29741440)

  • 1. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
    Moslehi JJ; Deininger M
    J Clin Oncol; 2015 Dec; 33(35):4210-8. PubMed ID: 26371140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
    Deb S; Boknäs N; Sjöström C; Tharmakulanathan A; Lotfi K; Ramström S
    Cancer Med; 2020 Jan; 9(1):313-323. PubMed ID: 31714021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
    Smith BD; Brümmendorf TH; Roboz GJ; Gambacorti-Passerini C; Charbonnier A; Viqueira A; Leip E; Purcell S; Goldman EH; Giles F; Ernst T; Hochhaus A; Rosti G
    Leuk Res; 2024 Apr; 139():107481. PubMed ID: 38484432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
    Yilmaz M; Jabbour E
    Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
    Aoyama T; Kuriyama H; Sato Y; Imai S; Kashiwagi H; Sugawara M; Takekuma Y
    Biol Pharm Bull; 2021; 44(8):1101-1110. PubMed ID: 34334496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.
    Yokoyama Y; Nozawa E; Morita M; Ishikawa E; Mori T; Sakurai M; Kikuchi T; Matsuki E; Yamazaki R; Kataoka K; Jibiki A; Kawazoe H; Suzuki S; Nakamura T
    J Clin Lab Anal; 2022 Aug; 36(8):e24598. PubMed ID: 35819095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
    Thienelt CD; Green K; Bowles DW
    Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should vascular effects of newer treatments be addressed more completely?
    Yang EH; Watson KE; Herrmann J
    Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
    [No Abstract]   [Full Text] [Related]  

  • 14. [Management using the plasma concentration of tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia: an update].
    Miura M; Takahashi N
    Rinsho Ketsueki; 2019; 60(9):1140-1147. PubMed ID: 31597837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib.
    Alkebsi L; Wang X; Ohkawara H; Fukatsu M; Mori H; Ikezoe T
    Int J Hematol; 2021 Mar; 113(3):441-455. PubMed ID: 33392972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponatinib reduces viability, migration, and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Shapira S; Raz O; Pasvolsky O; Nagler A; Lev DL; Inbal A; Lubin I; Raanani P; Leader A
    Leuk Lymphoma; 2017 Jun; 58(6):1455-1467. PubMed ID: 27733071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
    Wang Y; Travers RJ; Farrell A; Lu Q; Bays JL; Stepanian A; Chen C; Jaffe IZ
    PLoS One; 2023; 18(11):e0294438. PubMed ID: 37983208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia.
    Muresan B; Mamolo C; Cappelleri JC; Leip E; Viqueira A; Heeg B
    Curr Med Res Opin; 2021 May; 37(5):801-809. PubMed ID: 33733983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
    Casavecchia G; Spinosa G; De Gennaro L; Zicchino S; Gravina M; Magnesa M; Di Biase M; Brunetti ND
    Acta Cardiol; 2022 Apr; 77(2):130-135. PubMed ID: 33685352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
    Hochhaus A; Ernst T; Eigendorff E; La Rosée P
    Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.